Farms.com Home   Farm Equipment News

Confusion, Questions Largely Settled with Claas Announcement for N.D.

Questions (or gossip  if you want to call it that) about what was happening with the Claas contract in the Red River Valley was buzzing several times this spring after the conclusion of the wholegoods contract previously held by Butler Equipment. 

Claas’ North American headquarters in Omaha, meanwhile, remained “all quiet on the western front.” That is, until Ag Equipment Intelligence (AEI) staff – on its way to Sioux Falls, S.D., saw 3 Claas executives from Omaha waiting at a Minneapolis Delta gate bound for Fargo. The surprised execs admitted a new arrangement was in the final hours and to expect a forthcoming news release. 

Still mum, AEI pushed Claas for an announcement several times throughout the month of May. Finally, as Claas acknowledged that the “whispers have started,” AEI received a release embargoed until June 2.  

A Quick Turn of Events

In 2024, Ohio Ag, Ziegler Equipment and Butler Equipment each separated from Claas. 

Ziegler’s exit from the Claas contract in its Wisconsin and Missouri locations  — described by one observer as “too quick” to properly accommodate  all concerns — was regarded as “clumsy” by many in the industry. Butler Equipment, instead opted to work with Claas on a longer arrangement. In the August 2024 announcement, it reported that it would maintain the wholegoods contract for another 6 months (January 2025) and parts and service support through the end of 2026.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.